湿疹治療薬の世界市場:予測及び分析 2020-2024

LINEで送る

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• Value chain analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market size and forecast 2019-2024
• Market outlook
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 08: MARKET SEGMENTATION BY INDICATION
• Market segmentation by indication
• Comparison by indication
• Atopic dermatitis – Market size and forecast 2019-2024
• Contact dermatitis – Market size and forecast 2019-2024
• Other indication – Market size and forecast 2019-2024
• Market opportunity by indication
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Business strategies
• Geopolitical uncertainties
• Increasing healthcare expenditure
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Alliance Pharma Plc
• Bausch Health Companies Inc.
• Bayer AG
• Eli Lilly and Co.
• Encore Dermatology Inc.
• LEO Pharma AS
• Mylan NV
• Pfizer Inc.
• Sanofi
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendors: Key Offerings
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Customer landscape
Exhibit 19: Market share by geography 2019-2024 (%)
Exhibit 20: Geographic comparison
Exhibit 21: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 22: North America – Year-over-year growth 2020-2024 (%)
Exhibit 23: Top 3 countries in North America
Exhibit 24: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 25: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 26: Top 3 countries in Europe
Exhibit 27: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 28: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 29: Top 3 countries in Asia
Exhibit 30: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 31: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 32: Top 3 countries in ROW
Exhibit 33: Key leading countries
Exhibit 34: Market opportunity
Exhibit 35: Indication – Market share 2019-2024 (%)
Exhibit 36: Comparison by indication
Exhibit 37: Atopic dermatitis – Market size and forecast 2019-2024 ($ millions)
Exhibit 38: Atopic dermatitis – Year-over-year growth 2020-2024 (%)
Exhibit 39: Contact dermatitis – Market size and forecast 2019-2024 ($ millions)
Exhibit 40: Contact dermatitis – Year-over-year growth 2020-2024 (%)
Exhibit 41: Other indication – Market size and forecast 2019-2024 ($ millions)
Exhibit 42: Other indication – Year-over-year growth 2020-2024 (%)
Exhibit 43: Market opportunity by indication
Exhibit 44: Product launch details
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Business strategies
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AbbVie Inc. – Vendor overview
Exhibit 53: AbbVie Inc. – Business segments
Exhibit 54: AbbVie Inc. – Organizational developments
Exhibit 55: AbbVie Inc. – Geographic focus
Exhibit 56: AbbVie Inc. – Key offerings
Exhibit 57: AbbVie Inc. – Key customers
Exhibit 58: Alliance Pharma Plc – Vendor overview
Exhibit 59: Alliance Pharma Plc – Business segments
Exhibit 60: Alliance Pharma Plc – Organizational developments
Exhibit 61: Alliance Pharma Plc – Geographic focus
Exhibit 62: Alliance Pharma Plc – Segment focus
Exhibit 63: Alliance Pharma Plc – Key offerings
Exhibit 64: Alliance Pharma Plc – Key customers
Exhibit 65: Bausch Health Companies Inc. – Vendor overview
Exhibit 66: Bausch Health Companies Inc. – Business segments
Exhibit 67: Bausch Health Companies Inc. – Organizational developments
Exhibit 68: Bausch Health Companies Inc. – Geographic focus
Exhibit 69: Bausch Health Companies Inc. – Segment focus
Exhibit 70: Bausch Health Companies Inc. – Key offerings
Exhibit 71: Bausch Health Companies Inc. – Key customers
Exhibit 72: Bayer AG – Vendor overview
Exhibit 73: Bayer AG – Business segments
Exhibit 74: Bayer AG – Organizational developments
Exhibit 75: Bayer AG – Geographic focus
Exhibit 76: Bayer AG – Segment focus
Exhibit 77: Bayer AG – Key offerings
Exhibit 78: Bayer AG – Key customers
Exhibit 79: Eli Lilly and Co. – Vendor overview
Exhibit 80: Eli Lilly and Co. – Business segments
Exhibit 81: Eli Lilly and Co. – Organizational developments
Exhibit 82: Eli Lilly and Co. – Geographic focus
Exhibit 83: Eli Lilly and Co. – Segment focus
Exhibit 84: Eli Lilly and Co. – Key offerings
Exhibit 85: Eli Lilly and Co. – Key customers
Exhibit 86: Encore Dermatology Inc. – Vendor overview
Exhibit 87: Encore Dermatology Inc. – Product segments
Exhibit 88: Encore Dermatology Inc. – Organizational developments
Exhibit 89: Encore Dermatology Inc. – Key offerings
Exhibit 90: Encore Dermatology Inc. – Key customers
Exhibit 91: LEO Pharma AS – Vendor overview
Exhibit 92: LEO Pharma AS – Product segments
Exhibit 93: LEO Pharma AS – Organizational developments
Exhibit 94: LEO Pharma AS – Key offerings
Exhibit 95: LEO Pharma AS – Key customers
Exhibit 96: Mylan NV – Vendor overview
Exhibit 97: Mylan NV – Product segments
Exhibit 98: Mylan NV – Organizational developments
Exhibit 99: Mylan NV – Geographic focus
Exhibit 100: Mylan NV – Segment focus
Exhibit 101: Mylan NV – Key offerings
Exhibit 102: Mylan NV – Key customers
Exhibit 103: Pfizer Inc. – Vendor overview
Exhibit 104: Pfizer Inc. – Business segments
Exhibit 105: Pfizer Inc. – Organizational developments
Exhibit 106: Pfizer Inc. – Geographic focus
Exhibit 107: Pfizer Inc. – Segment focus
Exhibit 108: Pfizer Inc. – Key offerings
Exhibit 109: Pfizer Inc. – Key customers
Exhibit 110: Sanofi – Vendor overview
Exhibit 111: Sanofi – Business segments
Exhibit 112: Sanofi – Organizational developments
Exhibit 113: Sanofi – Geographic focus
Exhibit 114: Sanofi – Segment focus
Exhibit 115: Sanofi – Key offerings
Exhibit 116: Sanofi – Key customers
Exhibit 117: Validation techniques employed for market sizing
Exhibit 118: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様